Rationale and design of the valsartan heart failure trial: A large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure
- 1 June 1999
- journal article
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 5 (2) , 155-160
- https://doi.org/10.1016/s1071-9164(99)90038-6
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- A Clinical Trial of the Angiotensin-Converting–Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial InfarctionNew England Journal of Medicine, 1995
- Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure.Circulation, 1993
- Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial InfarctionNew England Journal of Medicine, 1992
- A Comparison of Enalapril with Hydralazine–Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart FailureNew England Journal of Medicine, 1991
- Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart FailureNew England Journal of Medicine, 1991
- Epidemiology of heart failureAmerican Heart Journal, 1991
- Angiotensin II-forming pathways in normal and failing human hearts.Circulation Research, 1990
- Angiotensin and the remodelling of the myocardium.British Journal of Clinical Pharmacology, 1989
- Effects of Enalapril on Mortality in Severe Congestive Heart FailureNew England Journal of Medicine, 1987
- Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure.Circulation, 1978